Ensysce Biosciences, Inc. (ENSC)
| Market Cap | 2.96M +1.9% |
| Revenue (ttm) | 4.71M -24.4% |
| Net Income | -11.79M |
| EPS | -3.01 |
| Shares Out | 9.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 697,598 |
| Open | 0.3134 |
| Previous Close | 0.3231 |
| Day's Range | 0.2950 - 0.3186 |
| 52-Week Range | 0.2300 - 2.7500 |
| Beta | 0.88 |
| Analysts | n/a |
| Price Target | 16.45 (+5,063.21%) |
| Earnings Date | May 15, 2026 |
About ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the... [Read more]
Financial Performance
In 2025, Ensysce Biosciences's revenue was $5.07 million, a decrease of -2.75% compared to the previous year's $5.21 million. Losses were -$10.18 million, 27.4% more than in 2024.
Financial StatementsNews
Ensysce Biosciences Reports First Quarter 2026 Financial Results
~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~ ~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~ ~ Company Launches Formal Review of...
Ensysce Biosciences Quarterly report: Q1 2026
Ensysce Biosciences has published its Q1 2026 quarterly earnings report on May 15, 2026.
Ensysce Biosciences Earnings release: Q1 2026
Ensysce Biosciences released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Ensysce announces expansion of patent protection for MPAR technology
Ensysce Biosciences (ENSC) announced that the Taiwan Intellectual Property Office issued a patent covering Ensysce’s MPAR technology. The patent, titled “Compositions Comprising Enzyme-Cleavable Prodr...
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage phar...
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
~ Chemical Control, Clinical Confidence: Rethinking Opioids ~ SAN DIEGO, CA / ACCESS Newswire / May 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pha...
Ensysce Biosciences Slides: Investor presentation
Ensysce Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 20, 2026.
Ensysce secures IRB approval of final phase of PF614-MPAR-102 study
Ensysce Biosciences (ENSC) announced Investigational Review Board approval to initiate Part 3 of the PF614-MPAR-102 clinical study, marking the final stage in this study evaluating its novel MPAR over...
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
~ Advances First-in-Class Opioid with Oral Overdose-Protection ~ SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-sta...
Ensysce Biosciences Registration statement: Registration filing
Ensysce Biosciences filed a registration statement on April 9, 2026, providing details about a securities offering with the SEC.
Ensysce Biosciences files to sell 20.34M shares of common stock for holders
06:05 EDT Ensysce Biosciences (ENSC) files to sell 20.34M shares of common stock for holders
Ensysce Biosciences secures second financing from 2025 agreement
Ensysce Biosciences (ENSC) announced the closing of a second convertible preferred stock financing of $2M under prior commitment in November 2025 of up to $20M funding available over 24 months.
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc. (NA...
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc. (NASDAQ:E...
Ensysce Biosciences Annual report: Q4 2025
Ensysce Biosciences has published its Q4 2025 annual report on March 30, 2026.
Ensysce Biosciences Earnings release: Q4 2025
Ensysce Biosciences released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
Ensysce Biosciences announces initiation of ‘Ask Me Anything’ series
Ensysce Biosciences (ENSC) announced the initiation of its live “Ask Me Anything” series on March 4.The event reinforced the Company’s commitment to transparency, accessibility, and open dialogue with...
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
~ Underscores Strategic Execution Plans, Regulatory Risk Mitigation Efforts, Pipeline Prioritization, and the Commercial Potential of PF614 ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 4, 2026 / ...
Ensysce Biosciences announces publication on MPAR technology
Ensysce Biosciences (ENSC) announced the publication of the first clinical manuscript describing its MPAR overdose protection technology. The paper, titled “Formulation and a Phase 1 Clinical Study of...
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
~ Phase 1 Data Published in Journal of Opioid Management Validates First-in-Class Overdose-Limiting Opioid Technology of PF614-MPAR ~ SAN DIEGO, CA / ACCESS Newswire / March 3, 2026 / Ensysce Bioscien...
Ensysce Biosciences initiates review of strategic alternatives
Ensysce Biosciences (ENSC) announced its Board of Directors has initiated a formal review of a broad range of strategic alternatives intended to enhance shareholder value and support the continued adv...
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 25, 2026 / Ensysc...
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 23, 2026 / E...
Ensysce Biosciences enrolls 50% of subjects in Phase 3 trial of PF614
Ensysce Biosciences (ENSC) has enrolled 50% of subjects targeted for interim review in its pivotal Phase 3 clinical trial of PF614, the Company’s next-generation opioid candidate engineered to deliver...
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a...